Company Overview: Onconova

Industry News

26 Jun

Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid

Oral Rigosertib combined with Azacitidine administered to patients with treatment naïve and refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes, demonstrates responses in difficult-to-treat population •  The combination may overcome hypomethylating agent resistance; further study in Acute Myeloid Leukemia is warranted Nonclinical study of Rigosertib combined with Azacitidine suggests epigenetic...

Read more

13 Jun

Onconova Therapeutics to Present at the BIO International Convention

NEWTOWN, Pa., June 13, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that Dr. Ramesh Kumar, President & CEO, will...

Read more

5 Jun

Onconova Therapeutics Announces Positive Phase 2 Data in Rigosertib Treated Patients with Second-line Myelodysplastic Syndromes at the American Society of Clinical Oncology Annual Meeting

NEWTOWN, Pa., June 05, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced the results of a Phase 2 study with...

Read more

15 May

Investor Network: Onconova Therapeutics Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 15, 2017 / Onconova Therapeutics Inc. (NASDAQ: ONTX) will be discussing their earnings results in their Q1 Earnings Call to be held 5/15/2017 at 9:00 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/22398. Replay Information The replay will...

Read more

27 Apr

Onconova Therapeutics Announces Closing of Public Offering of Common Stock

NEWTOWN, Pa., April 26, 2017 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced the closing of its previously announced public offering of...

Read more

Page 1 of 512345

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address